Osurnia Unión Europea - islandés - EMA (European Medicines Agency)

osurnia

dechra regulatory b.v. - betamethasone acetate, terbinafine, florfenicol - krefur og antiinfectives í samsetning - hundar - meðferð við bráðri utanbólgu.

Mirataz Unión Europea - islandés - EMA (European Medicines Agency)

mirataz

dechra regulatory b.v. - mírtasapín - psychoanaleptics, antidepressants in combination with psycholeptics - kettir - fyrir líkamsþyngd ná í ketti að upplifa léleg matarlyst og þyngd tap sem leiðir af langvarandi sjúkdóma.

Canaural (Fucidin comp. Vet.) Eyrnadropar, dreifa Islandia - islandés - LYFJASTOFNUN (Icelandic Medicines Agency)

canaural (fucidin comp. vet.) eyrnadropar, dreifa

dechra veterinary products a/s* - framycetinum súlfat; diaethanolaminum fusidas; nystatinum inn; prednisolonum inn - eyrnadropar, dreifa

Malaseb vet. Hársápa 2 % w/v Islandia - islandés - LYFJASTOFNUN (Icelandic Medicines Agency)

malaseb vet. hársápa 2 % w/v

dechra veterinary products a/s* - chlorhexidinum díglúkónat; miconazolum nítrat - hársápa - 2 % w/v

Spectrabactin Vet Tafla 200 mg/50 mg Islandia - islandés - LYFJASTOFNUN (Icelandic Medicines Agency)

spectrabactin vet tafla 200 mg/50 mg

dechra regulatory b.v. - amoxicillinum tríhýdrat; acidum clavulanicum kalíum - tafla - 200 mg/50 mg

Spectrabactin Vet Tafla 40 mg/10 mg Islandia - islandés - LYFJASTOFNUN (Icelandic Medicines Agency)

spectrabactin vet tafla 40 mg/10 mg

dechra regulatory b.v. - amoxicillinum tríhýdrat; acidum clavulanicum kalíum - tafla - 40 mg/10 mg

Lacosamide Adroiq Unión Europea - islandés - EMA (European Medicines Agency)

lacosamide adroiq

extrovis eu ltd. - lacosamíð - flogaveiki - antiepileptics, - lacosamide adroiq is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. lacosamide adroiq is indicated as adjunctive therapyin the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.